Table 5.
First line treatments (single and combination) among ASD cohort in in IBM MarketScan® Multi-State Medicaid Database
| Treatment | Patient count | % of patients in 1st treatment line |
|---|---|---|
| Anticonvulsant | 766 | 2.95 |
| Anticonvulsant + Behavioral and special therapy | 146 | 0.56 |
| Antipsychotics | 259 | 1.00 |
| Antipsychotics + other (atypical) Antipsychotics | 748 | 2.88 |
| Antipsychotics + Behavioral and special therapy + other (atypical) Antipsychotics | 253 | 0.97 |
| Centrally acting sympathomimetics | 1409 | 5.42 |
| Imidazoline receptor agonists | 1194 | 4.60 |
| Imidazoline receptor agonists + Centrally acting sympathomimetics | 169 | 0.65 |
| Imidazoline receptor agonists + Behavioral and special therapy | 321 | 1.24 |
| Selective serotonin reuptake inhibitors (SSRI) | 776 | 2.99 |
| Selective serotonin reuptake inhibitors (SSRI) + Behavioral and special therapy | 219 | 0.84 |
| Anxiolytics (excluding BZO) | 513 | 1.97 |
| Behavioral and special therapy | 14,359 | 55.27 |
| Behavioral and special therapy + Centrally acting sympathomimetics | 425 | 1.64 |
| hypnotics and sedatives | 910 | 3.50 |
| Other antidepressants | 295 | 1.14 |